论文部分内容阅读
肺癌是目前世界上发病率和死亡率均居首位的恶性肿瘤,其中大多数是非小细胞肺癌(non-small cell lung cancer,NSCLC)。在对NSCLC的治疗中,酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)的应用已成为靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)的重要治疗手段。但由于获得性耐药问题的出现,使得这类靶向药物的作用受到限制。近年来大量研究表明,除了基因突变等分子水平的因素外,细胞自噬(autophagy)在非小细胞肺癌EGFR-TKI靶向药物耐药中也发挥了重要的作用。该文重点就自噬与非小细胞肺癌EGFR-TKI靶向药物耐药的研究进展进行分析,旨在为解决自噬相关的EGFR-TKI耐药提供更多思路。
Lung cancer is the most malignant tumor in the world with the highest morbidity and mortality, most of which are non-small cell lung cancer (NSCLC). The use of tyrosine kinase inhibitor (TKI) has become an important therapeutic approach for targeting epidermal growth factor receptor (EGFR) in the treatment of NSCLC. However, due to the emergence of AMR, the role of such targeted drugs is limited. In recent years, a large number of studies have shown that autophagy plays an important role in EGFR-TKI targeted drug resistance in non-small cell lung cancer, in addition to molecular factors such as gene mutation. The paper focuses on the research progress of the drug-resistant EGFR-TKI target drug in autophagy and non-small cell lung cancer and aims to provide more ideas for solving the autophagy-related EGFR-TKI resistance.